Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168

Design Therapeutics (DSGN) announced favorable data from a Phase 1 single- and multiple-ascending dose, SAD/MAD, trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator Park City 2025, an event backed by the American Academy of Ophthalmology highlighting industry advancements and innovative new products disrupting eye care. Twenty-four healthy volunteers received either placebo or single- and multiple-ascending doses of DT-168 eye drops twice daily for seven days: DT-168 eye drops were well-tolerated in all participants; There were no serious adverse events, no ocular adverse events and no treatment discontinuations due to AEs in the trial. All observed AEs were deemed not related to DT-168 by the trial investigator; As expected, PK analysis demonstrated systemic exposure below the limit of quantitation for all participants across all timepoints and all dose groups.